Our name, Enara Bio®, is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in discovering and validating Dark Antigens®, a rich source of novel cancer targets derived from areas of the genome previously considered to be ‘dark’ or non-coding. Through our proprietary EnTiCE® platform, we are developing first-in-class bispecific T-cell engagers against novel targets to improve treatment outcomes for broad populations of cancer patients.

Enara Bio is backed by prominent life science investors, including RA Capital, Pfizer Ventures, M Ventures, Samsara BioCapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.